QuidelOrtho (QDEL) to Release Quarterly Earnings on Wednesday

QuidelOrtho (NASDAQ:QDEL - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.61 per share and revenue of $694.97 million for the quarter. QuidelOrtho has set its FY 2025 guidance at 2.070-2.570 EPS.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. On average, analysts expect QuidelOrtho to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

QuidelOrtho Price Performance

QuidelOrtho stock traded down $1.43 during trading hours on Monday, hitting $27.69. 2,032,598 shares of the company traded hands, compared to its average volume of 1,011,355. QuidelOrtho has a 1-year low of $23.77 and a 1-year high of $49.45. The company has a quick ratio of 0.69, a current ratio of 1.22 and a debt-to-equity ratio of 0.71. The firm's 50-day simple moving average is $32.34 and its two-hundred day simple moving average is $38.46. The firm has a market cap of $1.87 billion, a P/E ratio of -0.91 and a beta of 0.43.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. StockNews.com cut shares of QuidelOrtho from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. UBS Group upped their price objective on shares of QuidelOrtho from $43.00 to $45.00 and gave the stock a "neutral" rating in a research note on Thursday, February 13th. Royal Bank of Canada lowered their price objective on QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating for the company in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of QuidelOrtho from $38.00 to $25.00 and set an "underweight" rating for the company in a research report on Monday, April 21st. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $46.83.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.